We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
The potential benefits of a new class of medications, sodium-dependent glucose cotransporter-2 therapy (or SGLT-2s), for type 2 diabetes is promising, but where will they fit in the treatment of diabetes and what are the risks? Join host Dr. Steven Edelman and his guest, professor of medicine at the Veterans Affairs Medical Center in San Diego, California, Dr. Robert Henry, as they discuss the mechanism, benefits and potential cardiovascular risks of this new class of medication.
The potential benefits of a new class of medications, sodium-dependent glucose cotransporter-2 therapy (or SGLT-2s), for type 2 diabetes is promising, but where will they fit in the treatment of diabetes and what are the risks? Join host Dr. Steven Edelman and his guest, professor of medicine at the Veterans Affairs Medical Center in San Diego, California, Dr. Robert Henry, as they discuss the mechanism, benefits and potential cardiovascular risks of this new class of medication.
Stay current with the best on medical education
